Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Loading...
Thumbnail Image

Authors

Choi, Jennifer
Anderson, Ronald
Blidner, Ada Gabriela
Cooksley, Tim
Dougan, Michael
Glezerman, Ilya
Ginex, Pamela
Girotra, Monica
Gupta, Dipti
Johnson, Douglas

Journal Title

Journal ISSN

Volume Title

Publisher

Springer

Abstract

Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.

Description

Keywords

Bullous dermatoses, Corticosteroids, Cutaneous IrAEs, Inflammatory dermatitis, Pruritus, Skin rash, Vitiligo, Immune checkpoint inhibitor (ICI), Immune-related adverse events (IrAEs)

Sustainable Development Goals

Citation

Choi, J., Anderson, R., Blidner, A. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer 28, 6119–6128 (2020). https://doi.org/10.1007/s00520-020-05706-4.